Skip to main content

Afeyan Noubar's Form 4 filing

Omega Therapeutics, Inc.OMGA · filed Aug 5, 2021

Accession no.
0000899243-21-031796
Filed
Aug 5, 2021, 5:41 PM ET
Trade date
Aug 3, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 11 derivative transactions. Open-market purchases total $20.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Afeyan NoubarCIK 0001222012Director, 10% Owner
Flagship Pioneering, LLCCIK 000140024010% Owner
Flagship Pioneering Fund VI, L.P.CIK 000171692610% Owner
Flagship Pioneering Fund VI General Partner LLCCIK 000172495710% Owner
Flagship Pioneering Special Opportunities Fund II, L.P.CIK 000176128310% Owner
Nutritional Health LTP Fund General Partner LLCCIK 000178095110% Owner
Nutritional Health LTP Fund, L.P.CIK 000178095610% Owner
Flagship Pioneering Special Opportunities Fund II General Partner LLCCIK 000182621710% Owner
FPN General Partner LLCCIK 000186005910% Owner
FPN, L.P.CIK 000186006210% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 3, 2021Common StockCConversionAcquired+1,088,470–F1–1,088,470Indirect
Aug 3, 2021Common StockCConversionAcquired+5,896,386–F1–5,896,386Indirect
Aug 3, 2021Common StockCConversionAcquired+8,396,825–F1–8,396,825Indirect
Aug 3, 2021Common StockPPurchaseAcquired+220,588$17.00+$3,749,9968,617,413Indirect
Aug 3, 2021Common StockCConversionAcquired+970,588–F1–970,588Indirect
Aug 3, 2021Common StockCConversionAcquired+4,852,943–F1–4,852,943Indirect
Aug 3, 2021Common StockPPurchaseAcquired+661,764$17.00+$11,249,9885,514,707Indirect
Aug 3, 2021Common StockCConversionAcquired+1,323,529–F1–1,323,529Indirect
Aug 3, 2021Common StockPPurchaseAcquired+294,117$17.00+$4,999,9891,617,646Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 3, 2021Common StockCConversionDisposed−1,088,470–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−5,896,386–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−7,249,767–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−794,118–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−705,882–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−176,470–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−3,529,413–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−882,353–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−441,176–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−1,323,530–F1–0Indirect
Aug 3, 2021Common StockCConversionDisposed−441,176–F1–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.

Referenced by the price of 6 transactions in Table I and 11 transactions in Table II.

Remarks

Due to the limitations of the electronic filing system, each of Flagship Ventures Fund V General Partner LLC, Flagship V VentureLabs RX Fund, L.P., Flagship Ventures Fund V, L.P., Flagship VentureLabs V Manager LLC and Flagship VentureLabs V LLC are filing a separate Form 4. Each Form 4 will be filed by Designated Filer Flagship Pioneering, Inc.

Read the full filing on SEC EDGAR (opens in a new tab)